

Prostate 2023 Case Scenario

45-year-old male who presented with abnormal DRE, nodule/mass on LT-hand side noted with normal seminal vesicle, with elevated PSA of 14.9 taken on 5/9/2021.

5/9/2021: Prostate core bx

- a. Prostate, LT base: prostatic tissue with focal high grade prostatic intraepithelial neoplasia (HGPIN),
- b. Prostate, LT mid: adenocarcinoma of prostate. GS= 7(4+3), involving 60% of tissue, 1 out of 2 cores involved by tumor,
- c. Prostate, LT apex: adenocarcinoma of prostate. GS= 7(4+3), involving 90% of tissue, 2 out of 2 cores involved by tumor,
- d. Prostate, RT base: benign prostatic tissue,
- e. Prostate, RT mid: benign prostatic tissue,
- f. Prostate RT apex: small fragment suspicious for prostatic adenocarcinoma:
8 cores total taken

5/10/21: MRI pelvis: Lesion in LT mid-gland to apex peripheral zone and transitional zone with features consistent with prostate cancer. No evidence of pelvic lymphadenopathy. No EPE and No SVI identified.

5/18/21: Robotic-assisted total radical prostatectomy

Procedure: Radical prostatectomy

Histologic Type: Adenocarcinoma, mixed acinar and ductal type

Histologic Grade

Grade Group and Gleason Score: Grade group 2 (Gleason score 3 + 4)

Percentage of Pattern 4 in Gleason Score 7: 70%

Percentage of Pattern 5: 0%

Tumor Quantitation: Carcinoma present on 14 of 20 histologic sections

Extraprostatic Extension (EPE): Not identified

Urinary Bladder Neck Invasion: Not identified

Seminal Vesicle Invasion: Not identified

Margins: Negative for carcinoma

Treatment Effect on carcinoma: No known presurgical therapy

Lymphovascular Invasion: Not identified

Regional Lymph Nodes: No nodes submitted

Additional Pathologic Findings: High grade prostatic intraepithelial neoplasia

Worksheet

Primary Site	C619			Clinical Grade	3
Histology	8552/3			Pathological Grade	3
RLN pos	98	RLN examined	00	Post Therapy Grade	
Laterality	0				
LVI	0				
Tumor size clinical	999				
Tumor size path	999				
Tumor size summary	999				
Stage Data items					
AJCC Stage					
Clinical T	cT2	Pathological T	pT2	Post-therapy T	
cT Suffix		pT Suffix		pT Suffix	
Clinical N	cN0	Pathological N	pNX	Post-therapy N	
cN Suffix		pN Suffix		pN Suffix	
Clinical M	cM0	Pathological M	cM0	Post-therapy M	
Clinical Stage	2C	Pathological Stage	99	Post-therapy Stage	
Summary Stage 2018					
Summary Stage 2018		1-Localized			
<i>EOD Primary Tumor</i>		250			
<i>EOD Lymph Regional Nodes</i>		000			
<i>EOD Mets</i>		00			
<i>Prostate Pathologic Extension</i>		300			
SSDI's					
Gleason Patterns Clinical		43			
Gleason Patterns Pathological		34			
Gleason Score Clinical		07			
Gleason Score Pathological		07			
Gleason Tertiary Pattern		X9			
Number of Cores Positive		03			
Number of Cores Examined		08			
PSA		14.9			
Treatment					
Dx staging procedure	02				
Surgery reason no rx	0				
Surgical Approach at hospital	1				
Surgery course	1				
Surgery of primary site	50				
Scope of RLN surgery	00				
Surgery to other site	00				
Cancer Status	01			12/22/2022 Urologist note PSA <0.014	